Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Coherus BioSciences Inc CHRS

Healthcare Biotechnology
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. The Company’s immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and... see more

Recent & Breaking News (NDAQ:CHRS)

Coherus BioSciences Appoints Kimberly Tzoumakas, J.D. to Board of Directors

GlobeNewswire August 3, 2020

Coherus BioSciences Announces New Employment Inducement Grants

GlobeNewswire July 17, 2020

Coherus BioSciences to Report Second Quarter Financial Results on August 6th

GlobeNewswire July 16, 2020

Coherus BioSciences Announces New Employment Inducement Grants

GlobeNewswire June 19, 2020

Essent Group Set to Join S&P MidCap 400; Coherus BioSciences, Patterson-UTI Energy to Join S&P SmallCap 600

PR Newswire May 26, 2020

Coherus BioSciences Reports First Quarter 2020 Financial Results

GlobeNewswire May 7, 2020

Coherus BioSciences Management to Present at BofA Securities 2020 Health Care Conference

GlobeNewswire May 4, 2020

Coherus BioSciences to Report First Quarter Financial Results on May 7th

GlobeNewswire April 22, 2020

Coherus BioSciences Prices $200.0 Million Convertible Senior Subordinated Notes Offering

GlobeNewswire April 15, 2020

Coherus BioSciences Announces Proposed Convertible Senior Subordinated Notes Offering

GlobeNewswire April 14, 2020

Coherus BioSciences Provides First Quarter 2020 Financial Update and Fiscal Year 2020 COVID-19 Impact Insights

GlobeNewswire April 13, 2020

Coherus BioSciences Announces New Employment Inducement Grants

GlobeNewswire March 20, 2020

Coherus BioSciences Management to Present at Barclays Global Healthcare Conference 2020

GlobeNewswire March 5, 2020

United States Manufactured UDENYCA® (pegfilgrastim-cbqv) Well Positioned to Meet Market Demand

GlobeNewswire March 5, 2020

Coherus BioSciences Reports Fourth Quarter and Full Year 2019 Financial Results

GlobeNewswire February 27, 2020

Coherus BioSciences Management to Present at the 40th Annual Cowen Healthcare Conference

GlobeNewswire February 26, 2020

Coherus BioSciences Announces New Employment Inducement Grants

GlobeNewswire February 20, 2020

Coherus BioSciences to Report Fourth Quarter and Full Year Financial Results on February 27th

GlobeNewswire February 6, 2020

Coherus Acquires Commercial Rights for Avastin® Biosimilar in the United States

GlobeNewswire January 13, 2020

Coherus BioSciences Management to Present at the 38th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 3, 2020